TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03763162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study: NCT04095533

Intervention type: OTHER
Intervention: Muscle strength assessment
Description: Assessed using clinical bedside evaluation every second day with the Medical Research Council Sum Score. This is a clinical assessment of strength of 6 different muscle groups (shoulder abductors, elbow flexors, wrist extensors, hip flexors, knee extensors, and ankle dorsiflexors) on each side of the body and recorded as a score between 0 (flaccid) and 5 (full strength).
Study: NCT02259075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study: NCT02767544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal wound local analgesia after laparoscopic hysterectomy
Study: NCT00877097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Klodronate and Kliogest
Study: NCT01811953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: medium dose oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin/Metformin
Description: medium dose of Empagliflozin oral administration
Study: NCT03515707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV or oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04423835

Intervention type: PROCEDURE
Intervention: Paley's Principle osteotomy
Description: . The osteotomy line of all patients was designed according to Paley's principles. The lateral incision was applied in all patients and the osteotomy lines were marked on the humerus with the assistance of C-arm radiographs. An isosceles triangle template was used for osteotomy, and the medial cortex was left intact. K-wires were used to fix the osteotomy laterally.
Study: NCT02045849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 capsule
Description: Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 capsule
Description: Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 tablet
Description: Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 tablet
Description: Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944 tablet
Description: Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: Capsule containing Itraconazole with a unit dose strength of 100 mg
Study: NCT01916915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol infusion via wound catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol infusion via wound catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Study: NCT03763162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT00761163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (Non-exercise)
Description: The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
Study: NCT03373968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: suspension of givinostat (10 mg/mL)
Study: NCT04023981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parafricta bootees
Description: Parafricta bootees are a medical device designed to eliminate skin damage due to friction and shear. The basis of Parafricta bootees is a low friction material and bi-layer construction to make the material of the bootee slide on itself when movement of the foot would otherwise bring friction and shear to bear on the skin.
Study: NCT01912807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose (D5NS)
Description: Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (Control)
Description: Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
Study: NCT01608360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study: NCT01554410

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: 45 Gy in 25 daily fractions (1.8 Gy per fraction)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
Study: NCT01262235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKM-080301
Description: Repeat dose IV infusion.
Study: NCT03134664

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control group
Description: Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
Study: NCT02873845

Intervention type: OTHER
Intervention: Preliminary validation of the COBQoL questionnaire

Intervention type: OTHER
Intervention: Preliminary validation of the COBQoL questionnaire
Study: NCT05282407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil 245mg
Description: 1 tablet q.d. for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300mg
Description: 1 tablet q.d. for 48 weeks
Study: NCT03784300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg PTI-125
Description: PTI-125 50 mg Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50 mg PTI-125
Description: PTI-125 50 mg Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg PTI-125
Description: PTI-125 100 mg Oral Solution
Study: NCT00877097

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Kliogest

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bonefos
Study: NCT04958512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao pill
Description: The treatment group (20 cases) was treated with Yangxue Qingnao pill (2.5g / time, 3 times / day, orally for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydergotoxine mesylate tablets
Description: The control group (n = 20) was treated with hidezhen 3 mg per day before meals for 6 months

Intervention type: OTHER
Group type: OTHER
Intervention: blank control group
Description: There were 20 cases in the blank control group.Outpatient consultation at any time was prescribed.
Study: NCT01459939

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rose-hip powder capsules
Description: 5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
Study: NCT00936429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
Description: 3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)
Description: 3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DEN1-80E
Description: 3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
Study: NCT02496572

Intervention type: DRUG
Intervention: Short course MDR-TB treatment regimen
Description: Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration.
Study: NCT00910247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: 800 to 2400 mg once daily (QD)
Study: NCT03784924

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI prostate
Description: MRI and laboratory biomarkers
Study: NCT04633408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-C Virtual Training and Follow-up (STAR-VTF)
Description: STAR-C Virtual Training and Follow-up (STAR-VTF) is adapted from an evidence-based, in-person program that trains family caregivers to manage BPSD (behavioral and psychological symptoms of dementia)
Study: NCT00456807

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix TM
Description: Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT03328182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New oral endotracheal tube holder
Description: The single arm study product is designed to hold a standard or subglottic ET tube.
Study: NCT00003854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphangiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sentinel lymph node biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Study: NCT00790257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encapsulated human islets in a Monolayer Cellular Device
Description: The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.~One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation.
Study: NCT00622739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
Study: NCT03643614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of autologous regenerative cells of adipose tissue
Description: Autologous regenerative cells of adipose tissue obtained by enzymatic digestion of lipoaspirate are injected diffusively in the submucosal plane of the rectum and vagina with a sharp 27G needle. Adipose tissue that has not been subjected to enzymatic processing is injected through the punctures on the skin into the deep layers of the rectovaginal septum by means of cannula of 1.0-1.2 mm in diameter, 70 mm in length, 0.1-0.2 ml in one retrograde pass of the cannula.
Study: NCT01921088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)
Description: Subjects are provided with RT-fMRI-NF.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)
Description: Subjects are provided with RT-fMRI-NF.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ambulatory Training
Description: Subjects are provided with an ambulatory training.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Ambulatory Training
Description: Subjects are provided with an ambulatory training.
Study: NCT01631656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaic acid
Description: 15% gel on half the face, twice daily, 6 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:Yag laser
Description: Treatment with Nd:Yag laser , once at Week 2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:Yag laser
Description: Treatment with Nd:Yag laser , once at Week 2.
Study: NCT03784300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 100 mg PTI-125
Description: PTI-125 100 mg Oral Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 200 mg PTI-125
Description: PTI-125 200 mg Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 200 mg PTI-125
Description: PTI-125 200 mg Oral Solution
Study: NCT00003456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a newly diagnosed Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03849456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42006
Description: Oral solution containing cannabidivarin 50 milligrams per milliliter (mg/mL) in sesame oil with anhydrous ethanol, sucralose, strawberry flavoring, and β-carotene.
Study: NCT01189227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Description: Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy
Description: Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
Study: NCT02936271

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vasculera
Description: Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.~Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00366535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tabs b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 4 tabs b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: 4 tabs b.i.d.
Study: NCT03763162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00366535

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurotropin
Description: 4 tabs b.i.d.
Study: NCT02086279

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: GnRH analogue
Description: Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.~Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured.
Study: NCT00490412

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
Study: NCT04103606

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGBI: Positive Body Image (Mobile App)
Description: Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGBI: Positive Body Image (Mobile App)
Description: Brief, game-like, training exercise for challenging body image disorder symptoms and associated psychological features
Study: NCT02048189

Intervention type: DRUG
Group type: OTHER
Intervention: LEVEMIR

Intervention type: DRUG
Group type: OTHER
Intervention: APIDRA
Study: NCT03052543

Intervention type: DEVICE
Intervention: BIS™ Complete 2--Channel Monitor
Description: monitor depth of anesthesia

Intervention type: DEVICE
Intervention: BIS™ Complete 2--Channel Monitor
Description: monitor depth of anesthesia
Study: NCT04378452

Intervention type: BEHAVIORAL
Intervention: COM-COVID anonimous survey
Description: Anonimous e-survey administered to the general population by sharing it through social and mass media, including questions on sociodemographic data, physical symptoms in the past 14 days compatible with SARS-CoV-2 infection, socio-economic impact of the COVID-19 outbreak and psychological impact of the COVID-19 outbreak and mental health status.
Study: NCT01730846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 4mg/day
Description: 4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin 8mg/day
Description: 8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.